54 filings
8-K
MLYS
Mineralys Therapeutics Inc
14 Jun 24
Departure of Directors or Certain Officers
8:06am
8-K
MLYS
Mineralys Therapeutics Inc
10 Jun 24
Other Events
4:02pm
8-K
MLYS
Mineralys Therapeutics Inc
31 May 24
Financial Statements and Exhibits
4:06pm
8-K
MLYS
Mineralys Therapeutics Inc
22 May 24
Submission of Matters to a Vote of Security Holders
4:38pm
10-Q
2024 Q1
MLYS
Mineralys Therapeutics Inc
Quarterly report
9 May 24
7:10am
8-K
ns7z1ti7lvw3b460pogm
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
EFFECT
1d36a cuv2j21
12 Apr 24
Notice of effectiveness
12:15am
424B5
p39bdj
11 Apr 24
Prospectus supplement for primary offering
4:35pm
ARS
5f01ctrhjczm7c q8n56
9 Apr 24
Annual report to shareholders
7:21am
DEFA14A
71m7nll c4xmk
9 Apr 24
Additional proxy soliciting materials
7:18am
DEF 14A
likv ykck1
9 Apr 24
Definitive proxy
7:15am
8-K
s6vroz5rvc8lxkqs0
4 Apr 24
Departure of Directors or Certain Officers
8:04am
S-3/A
bb1k ff2gb
29 Mar 24
Shelf registration (amended)
4:44pm
8-K
zsfn8cqqo oybdtm
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
S-3
zpyf4xd 3ob51w
21 Mar 24
Shelf registration
7:30am
8-K
gsz jt0stci
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
uow 1a1jzm
4 Jan 24
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
4:10pm
8-K
wd3hzt b0h6wn
22 Dec 23
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
9:04am
8-K
aalqxn7 3giw53o6v5qk
13 Nov 23
Regulation FD Disclosure
8:20am